Protagonist Therapeutics Inc [PTGX] stock is trading at $55.23, up 4.21%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PTGX shares have gain 10.75% over the last week, with a monthly amount drifted -0.20%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on June 17, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $72. Previously, Goldman started tracking the stock with Neutral rating on December 06, 2024, and set its price target to $47. On December 06, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $62 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $58 on November 05, 2024. TD Cowen initiated its recommendation with a Buy and recommended $65 as its price target on September 24, 2024. Truist started tracking with a Buy rating for this stock on September 09, 2024, and assigned it a price target of $60. In a note dated October 30, 2023, CapitalOne initiated an Overweight rating and provided a target price of $32 on this stock.
Protagonist Therapeutics Inc [PTGX] stock has fluctuated between $32.50 and $60.60 over the past year. Currently, Wall Street analysts expect the stock to reach $73 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $55.23 at the most recent close of the market. An investor can expect a potential return of 32.17% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 207.80M for the trailing twelve months, which represents a drop of -88.89%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.09 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.77 points at the first support level, and at 52.30 for the second support level. However, for the 1st resistance point, the stock is sitting at 56.05, and for the 2nd resistance point, it is at 56.87.
Ratios To Look Out For
For context, Protagonist Therapeutics Inc’s Current Ratio is 17.26. As well, the Quick Ratio is 17.26, while the Cash Ratio is 3.98. Considering the valuation of this stock, the price to sales ratio is 16.47, the price to book ratio is 4.96 and price to earnings (TTM) ratio is 72.60.
Transactions by insiders
Recent insider trading involved MOLINA ARTURO MD, Chief Medical Officer, that happened on Jun 10 ’25 when 10000.0 shares were sold. Chief Medical Officer, MOLINA ARTURO MD completed a deal on Jun 09 ’25 to sell 10000.0 shares. Meanwhile, Officer ARTURO MOLINA bought 10000.0 shares on Jun 10 ’25.
